当前位置:
X-MOL 学术
›
Ann. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding
Annals of Oncology ( IF 56.7 ) Pub Date : 2017-07-19 , DOI: 10.1093/annonc/mdx251 C. Resteghini , L.D. Locati , P. Bossi , C. Bergamini , M. Guzzo , L. Licitra
Annals of Oncology ( IF 56.7 ) Pub Date : 2017-07-19 , DOI: 10.1093/annonc/mdx251 C. Resteghini , L.D. Locati , P. Bossi , C. Bergamini , M. Guzzo , L. Licitra
Lenvatinib has proved to be an effective but quite toxic therapeutic tool for differentiated thyroid carcinomas (DTCs), with two third of pts needing dose reduction and 14.2% discontinuing treatment in the SELECT trial [1]. Severe bleeding has been reported as one of the main cause of death in DTC pts treated with multi-target TKI [2].
中文翻译:
请勿将婴儿带洗澡水:选择个性化的,逐步降低的lenvatinib时间表,以便在局部晚期DTC中做出反应,同时控制与药物相关的主要出血
Lenvatinib已被证明是分化甲状腺癌(DTC)的有效但毒性相当大的治疗工具,在SELECT试验中,三分之二的患者需要降低剂量,停药的比例为14.2%[1]。据报道,使用多靶点TKI治疗后,严重出血是DTC pts死亡的主要原因之一[2]。
更新日期:2017-09-18
中文翻译:
请勿将婴儿带洗澡水:选择个性化的,逐步降低的lenvatinib时间表,以便在局部晚期DTC中做出反应,同时控制与药物相关的主要出血
Lenvatinib已被证明是分化甲状腺癌(DTC)的有效但毒性相当大的治疗工具,在SELECT试验中,三分之二的患者需要降低剂量,停药的比例为14.2%[1]。据报道,使用多靶点TKI治疗后,严重出血是DTC pts死亡的主要原因之一[2]。